Assertio Recommends Zydus' $23.50 All-Cash Acquisition Offer, Terminates Garda Deal
ASRT has more than doubled off its 52-week low of $8.61 on elevated volume (5.8× avg).
Summary
Assertio Holdings' Board recommends an all-cash acquisition by Zydus Worldwide DMCC for $23.50 per share, terminating a prior agreement with Garda Therapeutics for a higher offer.
Key Events · M&A and Partnerships · ASRT
-
Definitive Acquisition Agreement
Assertio Holdings, Inc. has entered into a definitive agreement to be acquired by Zydus Worldwide DMCC.
-
All-Cash Offer Price
Zydus will acquire all outstanding shares for $23.50 per share in cash, representing a premium over the current trading price and the 52-week high.
-
Prior Agreement Terminated
The company terminated its previous merger agreement with Garda Therapeutics, which offered $21.00 per share, after determining the Zydus proposal was a 'Superior Proposal'.
-
Board Recommendation
Assertio's Board of Directors has unanimously recommended the Zydus tender offer to its shareholders.
Analysis · ASRT · Life Sciences
Assertio Holdings' Board of Directors has formally recommended the all-cash tender offer from Zydus Worldwide DMCC for $23.50 per share. This definitive acquisition agreement provides a significant premium to shareholders, especially considering the stock is trading near its 52-week high. The company terminated its previous merger agreement with Garda Therapeutics, deeming the Zydus proposal a 'Superior Proposal,' which underscores the board's commitment to maximizing shareholder value.
At the time of this filing, ASRT was trading at $23.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.7M. The 52-week trading range was $8.61 to $23.36. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.